A new experimental osteoporosis drug, denosumab (Amgen) has shown to reduce the risk of vertebral fractures in post-menopausal women by 68% compared with patients taking a placebo in a pivotal clinical trial.
A new experimental osteoporosis drug, denosumab (Amgen) has shown to reduce the risk of vertebral fractures in post-menopausal women by 68% compared with patients taking a placebo in a pivotal clinical trial.